YAMAMOTO RESEARCH
|
YAMAMOTO® RESEARCH
Yamamoto® Research Inteflor BIMBI - Food supplement based on live bacterial cultures Inteflor BIMBI is a live bacterial cultures (Lactobacillus acidophilus PBS066, Bifidobacterium lactis BL050, Lactobacillus plantarum PBS067) food supplement suitable for children.
Studies demonstrating the positive effects of probiotics on various aspects of health in both adults and children have become increasingly widespread in recent years. Probiotics have the function of keeping the intestinal microbiota in balance with important benefits that extend not only to the gut but to the whole body.
"According to the World Health Organisation, probiotics are live organisms that, when administered in adequate amounts, benefit the health of the host." Probiotics are 'live' micro-organisms that can benefit and support intestinal health and efficiency, which means the whole body, aiding in digestion and absorption, as well as performing defensive functions such as countering the prevalence of pathogenic bacteria and preventing their proliferation, and stimulating the immune system. Children are also particularly susceptible to alterations in the balance of intestinal bacterial flora, and to attacks from external pathogens, which is why it is important to try to support their immune defences. Keeping the intestinal bacterial flora in balance means 'arming' the first line of defence against pathogens. Among the most frequent causes of intestinal imbalances in children are various forms of infection, incorrect diet and antibiotic treatment, which can lead to altered states of bacterial flora in the intestine, i.e. dysbiosis. INTEFLOR is a food supplement recommended for children, based on Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus plantarum, indicated to maintain the correct balance of the intestinal microbiota, which is fundamental in carrying out the physiological functions of the intestine, from digestion, to absorption, to the elimination of harmful substances and in particular to stimulate and support the immune system and to combat various gastrointestinal disorders such as acute infectious diarrhoea or dysbiosis following antibiotic therapy. SCIENTIFIC REFERENCES Wieërs G, Belkhir L, Enaud R, Leclercq S, Philippart de Foy JM, Dequenne I, de Timary P, Cani PD. How Probiotics Affect the Microbiota. Front Cell Infect Microbiol. 2020 Jan 15;9:454. doi: 10.3389/fcimb.2019.00454. PMID: 32010640; PMCID: PMC6974441. Szajewska H, Canani RB, Guarino A, Hojsak I, Indrio F, Kolacek S, Orel R, Shamir R, Vandenplas Y, van Goudoever JB, Weizman Z; ESPGHAN Working Group for ProbioticsPrebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):495-506. doi: 10.1097/MPG.0000000000001081. PMID: 26756877. Vanderhoof JA, Young RJ. Use of probiotics in childhood gastrointestinal disorders. J Pediatr Gastroenterol Nutr. 1998 Sep;27(3):323-32. doi: 10.1097/00005176-199809000-00011. PMID: 9740206. Wang Y, Li X, Ge T, Xiao Y, Liao Y, Cui Y, Zhang Y, Ho W, Yu G, Zhang T. Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016 Aug;95(31):e4509. doi: 10.1097/MD.0000000000004509. PMID: 27495104; PMCID: PMC4979858. Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019 Apr 30;4(4):CD004827. doi: 10.1002/14651858.CD004827.pub5. PMID: 31039287; PMCID: PMC6490796. Guarino A, Guandalini S, Lo Vecchio A. Probiotics for Prevention and Treatment of Diarrhea. J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S37-45. doi: 10.1097/MCG.0000000000000349. PMID: 26447963. do Carmo MS , Santos CID , Araújo MC , Girón JA , Fernandes ES , Monteiro-Neto V . Probiotics, mechanisms of action, and clinical perspectives for diarrhea management in children. Food Funct. 2018 Oct 17;9(10):5074-5095. doi: 10.1039/c8fo00376a. PMID: 30183037. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2014 Apr 10;(4):CD005496. doi: 10.1002/14651858.CD005496.pub4. Update in: Cochrane Database Syst Rev. 2020 Oct 15;10:CD005496. PMID: 24723255. Directions: take 1 sachet a day directly into the mouth.
|
14 sachets |
Cream |
Nutrition facts | |
Daily dose: 1 sachet | |
Servings per container: 14 | |
Per daily dose (1 sachet) | |
Lactobacillus acidophilus PBS066
(SynBalance ® LA 200B) |
50 mg - 2 x 10 9 UFC / CFU / UFC / UFC / KBE* |
Bifidobacterium lactis BL050
(SynBalance ® BL 300B) |
33,3 mg - 2 x 10 9 UFC / CFU / UFC / UFC / KBE* |
Lactobacillus plantarum PBS067
(SynBalance ® LP 500P) |
20 mg - 2 x 10 9 UFC / CFU / UFC / UFC / KBE* |
*CFU: colony-forming units | |
Ingredients: maltodextrin, bulking agent: sorbitol; Lactobacillus acidophilus PBS066 (DSM 24936) SynBalance ® LA 200B, Bifidobacterium lactis BL050 (DSM 25566) SynBalance ® BL 300B, Lactobacillus plantarum PBS067 (DSM 24937) SynBalance ® LP 500P, flavouring, anti-caking agent: silicon dioxide; sweetener: sucralose.
|